当前位置: 首页 >> 检索结果
504. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.
作者: Jie Gao.;Mengtao Li.;Ming Sun.;Yiyi Yu.;Ruina Kong.;Xia Xu.;Suxuan Liu.;Qian Chen.;Xiaofang Li.;Yang Wu.;Enshun Xu.;Jianmin Yang.;Dongbao Zhao.
来源: Lancet. 2026年406卷10522期2968-2979页
Lately, autologous CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent efficacy in treatment of autoimmune diseases, but with great safety concerns, such as infections. In this study, we aimed to evaluate the safety, tolerability, and efficacy of allogeneic CD19 CAR natural killer (NK)-cell therapy in patients with relapsed or refractory systemic lupus erythematosus (SLE).
505. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
作者: Mazen Noureddin.;Stephen A Harrison.;Rohit Loomba.;Naim Alkhouri.;Naga Chalasani.;Muhammad Y Sheikh.;Shaheen Tomah.;Julio A Gutierrez.;Silvia Urbina.;John J Suschak.;Randy Brown.;Ozioma Odili.;Jay Yang.;Stephine Keeton.;Guy Neff.;Edward Mena.;M Scot Roberts.;Sarah K Browne.;M Scott Harris.
来源: Lancet. 2025年406卷10520期2644-2655页
GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment.
507. Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
作者: Anette-Gabriele Ziegler.;Peter Achenbach.;Andreas Weiß.;Reinhard Berner.;Kristina Casteels.;Helena Elding Larsson.;Florian Haupt.;Angela Hommel.;An Jacobs.;Olga Kordonouri.;Markus Lundgren.;Mariusz Ołtarzewski.;Markus Pfirrmann.;Matthew D Snape.;Agnieszka Szypowska.;John A Todd.;Manu Vatish.;Thekla von dem Berge.;Christiane Winkler.;Ezio Bonifacio.; .
来源: Lancet. 2025年406卷10519期2564-2576页
Type 1 diabetes begins with autoimmunity against pancreatic islet antigens, including insulin. The aim of the Primary Oral Insulin Trial (POInT) was to evaluate the efficacy and safety of daily high-dose oral insulin to prevent the development of islet autoantibodies and diabetes.
510. The effects of government-led cash transfer programmes on behavioural and health determinants of mortality: a difference-in-differences study.
作者: Aaron Richterman.;Tra-My Ngoc Bùi.;Elizabeth F Bair.;Gregory Jerome.;Christophe Millien.;Jean Christophe Dimitri Suffrin.;Jere R Behrman.;Harsha Thirumurthy.
来源: Lancet. 2025年406卷10520期2656-2666页
Poverty is strongly associated with numerous adverse health outcomes. Government-led cash transfer programmes are crucial to poverty reduction strategies in many low-income and middle-income countries (LMICs). Although extensive research from individual programmes exists on the effects of cash transfers on beneficiaries, evidence of these programmes' population-wide health effects remains scarce. Previously, we showed that cash transfer programmes are associated with substantially reduced mortality rates among women and young children at the population level in LMICs. In this study, we aimed to explore the mechanisms underlying these reductions.
512. Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.
作者: Shamir R Mehta.;Denise T W Tiong.;Felix Böhm.;Chinthanie Ramasundarahettige.;Simone Biscaglia.;Gianluca Campo.;Stefan James.;Pieter C Smits.;Daniele Giacoppo.;Gerry P McCann.;Amerjeet Banning.;Dan Eik Høfsten.;Gianni Casella.;Faith R Kirabo.;Helen Nguyen.;David A Wood.;John A Cairns.;Thomas Engstrøm.
来源: Lancet. 2025年406卷10521期2772-2781页
In patients presenting with acute coronary syndromes and multivessel coronary artery disease, the question of whether to undertake a strategy of complete revascularisation in cases in which percutaneous coronary intervention (PCI) is performed routinely on non-culprit lesions (in addition to the culprit lesion) or whether to restrict PCI only to the culprit lesion is a common dilemma. The Complete Revascularisation Trialists' Collaboration aimed to determine, based on the totality of data from randomised trials, the effect of a complete revascularisation strategy on major cardiovascular events and whether it reduces cardiovascular death.
513. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
作者: Hiddo J L Heerspink.;José F Cardona.;Shivinder Jolly.;Pablo E Pergola.;Erika de Sousa-Amorim.;Anna L Eriksson.;Martin Fredholm.;Samvel B Gasparyan.;Nicolas J Guzman.;Judith Hartleib-Geschwindner.;Yunyun Jiang.;Maria Leonsson-Zachrisson.;Patrick B Mark.; .
来源: Lancet. 2025年406卷10518期2449-2460页
Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce albuminuria and risk of progression of chronic kidney disease. Non-steroidal mineralocorticoid receptor antagonists (MRA) have similar effects in patients with type 2 diabetes with chronic kidney disease. We aimed to assess efficacy and safety of the novel MRA balcinrenone combined with the SGLT2 inhibitor dapagliflozin in a randomised controlled trial.
515. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.
作者: Jeffrey I Weitz.;Aaron P Kithcart.;Meagan P O'Brien.;Oren Levy.;Ethan Marin.;Margaret Onisko.;Kusha A Mohammadi.;Dateng Li.;Karoline A Meagher.;Hannah H Chang.;Benjamin A Olenchock.;David E Gutstein.;Annelise Segers.;Robin S Roberts.;Marc P Bonaca.;Gary E Raskob.
来源: Lancet. 2025年406卷10519期2551-2563页
Coagulation factor XI (FXI) inhibitors can reduce the incidence of thrombosis without increasing bleeding risk. FXI is activated by factor XIIa (FXIIa) or thrombin. REGN7508Cat is an antibody that binds to the FXI catalytic domain, blocking both its activity and activation by FXIIa and thrombin. REGN9933A2 binds to the FXI apple 2 domain and blocks FXI activation by FXIIa. We aimed to compare the efficacy and safety of REGN9933A2 and enoxaparin, with apixaban as an exploratory comparator, and REGN7508Cat and enoxaparin for venous thromboembolism prevention.
518. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.
Chronic kidney disease (CKD) is common and ranks among the leading causes of mortality and morbidity. This analysis aimed to present global CKD estimates using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 to inform evidence-based policies for CKD identification and treatment.
519. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
作者: Liana K Billings.;Stanley Hsia.;Harold Bays.;Beth Tidemann-Miller.;Jessica O'Hagan.;Lai San Tham.;Annabelle Butler.;Christof Kazda.;Kieren J Mather.;Tamer Coskun.
来源: Lancet. 2025年406卷10520期2631-2643页
Amylin-based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management. We performed a phase 2, double blind, randomised, placebo-controlled trial with the aim of evaluating the efficacy and safety of a range of doses and dose escalation schemes of once-per-week eloralintide versus placebo in adults with obesity or overweight and had at least one weight-related comorbidity.
|